Vantis Vascular announced today announced the first commercial use of its CrossFast integrated microcatheter advanced delivery system.
Physicians used CrossFast in a series of ten successful complex high-risk coronary interventional procedures (CHiP). Dr. Amir Kaki performed the first case at St. John’s Hospital in Detroit.
Initial cases demonstrated 100% procedural success. Vantis reports quick, reliable delivery to the target location, successful stent delivery and no device-related complications.
“CHiP procedures often involve patients with multiple comorbidities, tortuous anatomy and significant disease, requiring specialized tools to deliver percutaneous therapies,” said Kaki. “The CrossFast advanced delivery system performed exceptionally well due to its ability to safely and efficiently navigate tight, highly calcified vessels. Despite the challenging anatomy, CrossFast was easily advanced, enabling stent delivery to the lesion which otherwise would have been difficult and time-consuming.
“This advanced delivery system is whole new class of device that exceeds performance of traditional guide extensions making this a welcomed tool in the complex operator’s toolbox.”
More about the Vantis Vascular CrossFast system
CrossFast, a dual monorail microcatheter delivery system, helps physicians perform faster, easier and safer procedures. The guide extension catheter offers additional support and facilitates device delivery in challenging anatomies and complex, high-risk cases. DuoPro interlocking technology allows the system to act as one unit for enhanced pushability and efficient navigation.
The CrossFast system won FDA clearance in October. Vantis Vascular currently has it available in the U.S. under a limited release. The company plans for a full launch later this year. The company also has the CrossShock intravascular lithotripsy (IVL) system under development.
Physicians also reported superior deliverability during highly complex cases. In these cases, a traditional guide extension catheter failed to reach the target lesion. They swapped it out for CrossFast and delivered the system with ease, according to a news release.
“We are thrilled with the early performance of the CrossFAST System,” said Dr. Frank Saltiel, chief clinical officer. “The device’s ability to navigate complex coronary anatomy with ease has the potential to revolutionize the way we approach CHiP procedures. We are confident that CrossFAST will play a crucial role in advancing coronary therapy by decreasing procedure times and reducing complications in patients with complex, difficult-to-treat lesions.”
